RADIX PHARMACEUTICALS, INC.

Basic Information

13303 Sunny Brooke Place
Room 101
Potomac, MD, -

Company Profile

n/a

Additional Details

Field Value
DUNS: 142006910
Hubzone Owned: N
Socially and Economically Disadvantaged: N
Woman Owned: N
Number of Employees: n/a


  1. Development of Small Molecules as Antiprotozoal Agents

    Amount: $1,240,336.00

    DESCRIPTION (provided by applicant): The proposed research focuses on the development of novel therapeutic agents for the prevention and treatment of malaria caused by P. falciparum. A previous Phase ...

    SBIR Phase II 2012 Department of Health and Human Services
  2. Preclinical Studies of Natural Product Derivatives as Antimalarial Agents

    Amount: $998,181.00

    DESCRIPTION (provided by applicant): This project focuses on the development of a novel therapeutic agent for preventing and treating P. falciparum malaria. A two-year Phase I research has discovered ...

    SBIR Phase II 2011 Department of Health and Human Services
  3. Isolation and Antimalarial Activity of Small Molecules from Ocimum sanctum

    Amount: $600,000.00

    DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a new drug (new chemical entity [NCE]) that is inexpensive, orally active, non-toxic and can provide cure for P. f ...

    SBIR Phase I 2008 Department of Health and Human Services
  4. Pre-Clinical Evaluation of Antimalarial Natural Products from Carica papaya L.

    Amount: $590,628.00

    DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a new drug (new chemical entity [NCE]) that is inexpensive, orally active, non-toxic and can provide cure for P. f ...

    SBIR Phase I 2008 Department of Health and Human Services
  5. Development of Natural Product as Antimalarial Agent

    Amount: $299,880.00

    DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a new drug (new chemical entity [NCE]) that is inexpensive, orally active, non-toxic and can provide cure for P. f ...

    SBIR Phase I 2007 Department of Health and Human Services
  6. Pre-Clinical Development of Natural Product Analogues as Antimalarial Agents

    Amount: $604,800.00

    DESCRIPTION (provided by applicant): The long-term goal of this project is to develop a new drug (new chemical entity [NCE]) that is inexpensive, orally active, non-toxic and can provide cure for P. f ...

    SBIR Phase II 2006 Department of Health and Human Services
  7. Synthesis and Evaluation of Novel Antimalarial Agents

    Amount: $100,000.00

    DESCRIPTION (provided by applicant): The long-term goal of this research is to develop drugs that are safe and effective against drug-resistant malaria. Malaria is one of the most common infectious di ...

    SBIR Phase I 2005 Department of Health and Human Services

Agency Micro-sites

US Flag An Official Website of the United States Government